1. Therapeutic efficacy of the somatostatin analog SMS 201-995 (octreotide) in acromegaly: effects of dose and frequency and long term safety;Ho, K.Y.; Weissberger, A.J.; Marbach, P.; Lazarus, L.;Ann Intern Med,1990
2. The French SMS 201-995 Acromegaly Study Group. Long terrm effect of incremental doses of the somatostatin analog SMS 201-995 in 58 acromegalic patients. J7 Clin Endocrinol Metab;Sassolas, G.; Harris, A.G.; James-Deidier, A.,1990
3. Why does somatostatin cause gallstones?;Ahrendt, S.A.; McGuire, G.E.; Pitt, H.A.; Lillemoe, K.D.,1991
4. Sonographic measurement of gallbladder volume;Dodds, W.J.; Groh, W.J.; Darweesh, R.M.A.; Lawson, T.L.; Kishk, S.M.A.; Kern, M.K.,1985
5. Post-prandial gallbladder motility during long-term treatment with the long-acting somatostatin analog SMS 201-995 in acromegaly. J7 Clin Endocrinol Metab;Liessum, P.A.; Hopman, W.P.M.; Pieters, G.F.F.M.; Jansen, J.B.M.; Smals, A.G.H.; Rosenbusch, G.,1989